Mseddi Mourad

Dr. Mseddi Mourad

Pharmacology, Hôpital Cochin, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FPFlorent Puisset
Florent Puisset
MMMseddi Mourad
Mseddi Mourad
LMLoïc Mourey
Loïc Mourey
DPDamien Pouessel
Damien Pouessel
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
CCChristine Chevreau
Christine Chevreau
Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale to develop therapeutic drug monitoring for these drugs. General considerations of such monitoring of the several groups of anticancer drugs are given, with a focus on oral therapy. Pharmacokinetics and the factors of inter- and intraindividual variabilities of these tyrosine kinase inhibitors are described together with an exhaustive presentation of their pharmacokinetic/pharmacodynamic relationships. The latter was observed in studies where every patient was treated with the same dose, and the results of several prospective studies based on dose individualization support the practice of increasing individual dosage in case of low observed plasma drug concentrations. Finally, the benefits and limits of therapeutic drug monitoring as a routine practice are discussed.

1 February 2007 in Archives de Pédiatrie
Verified
Journal Article
Closed access
MMMseddi Mourad
Mseddi Mourad
ADA. Dammak
A. Dammak
SMS. Marrekchi
S. Marrekchi
SBS. Bouassida
S. Bouassida
AZA. Zahaf
A. Zahaf
HTH. Turki
H. Turki

19 November 2019 in Annales de Dermatologie et de Vénéréologie
Verified
Journal Article
Closed access
FHF. Hammami
F. Hammami
SMS. Miladi
S. Miladi
MAM. Amouri
M. Amouri
EBE. Bahloul
E. Bahloul
AMA. Masmoudi
A. Masmoudi
HTH. Turki
H. Turki

18 February 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
MMMseddi Mourad
Mseddi Mourad
CNChrista Nath
Christa Nath
KHKhalil Ben Hassine
Khalil Ben Hassine
VMVid Mlakar
Vid Mlakar
YGYvonne Gloor
Yvonne Gloor
MAMarc Ansari
Marc Ansari
Fludarabine (Flu), administered as a prodrug Flu monophosphate, is a lymphodepleting agent used prior to hematopoietic stem cell transplantation (HSCT) which exhibits substantial pharmacokinetics (PK) variability, contributing to suboptimal outcomes. This study developed and validated a physiologically based pharmacokinetic (PBPK) model using literature‐based data and a middle‐out approach for Flu and its two main metabolites in adults and children, and evaluated its performance to predict individual Flu exposures in 28 pediatric HSCT patients using a virtual twin (VT) approach using PK‐Sim software. Different informed models with individual demographic and biological characteristics were assessed by comparing predicted and observed plasma exposures (AUC 0➔24h ) via fold error metrics and regression analyses. The PBPK model accurately reproduced observed Flu and metabolites concentrations in both adults and children. In the VT cohort, informing the model with plasma protein scaling factor and nuclear GFR improved drug exposure predictions in total (mean fold error (MFE) = 0.91) and unbound (MFE = 0.88) compartments with minimal bias in both Deming and Bland–Altman analyses. This model provided superior agreement between observed and predicted exposures, achieving improved agreement across statistical and regression approaches compared to the model with estimated GFR. PBPK‐based VT modeling enables accurate, individualized prediction of Flu PK in pediatric HSCT patients. These results support the implementation of model‐informed precision dosing to achieve personalized pediatric dosing of Flu in HSCT.